Seo Eoi Jong, Lee Joo Yong
Department of Ophthalmology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
J Ophthalmol. 2018 Sep 27;2018:2376240. doi: 10.1155/2018/2376240. eCollection 2018.
BACKGROUND/AIM: The aim of the study was to investigate the outcomes of temporal Zone II-sparing laser photocoagulation combined with intravitreal bevacizumab (IVB) in patients with Type 1 retinopathy of prematurity (ROP) in Zone I.
Medical records of 74 eyes of 37 infants were analysed. Only infants with Type 1 ROP in Zone I were included. Thirty-two eyes were treated with temporal-sparing laser + IVB. Both Zone I and temporal Zone II were spared to minimise potential visual field loss. Forty-two eyes were treated with laser alone conventionally. Early treatment outcomes, late complications, and refractive errors were analysed.
The mean gestational age and birth weight of the enrolled patients were 25.7 ± 2.5 weeks and 798.8 ± 440.2 g, respectively. In the combined treatment group, plus sign regression was achieved faster (12.1 ± 6.2 days vs. 25.6 ± 21.3 days, =0.011) and retreatment was required less (0% vs. 23.8%, =0.004) than in the laser-alone group. Retinal/preretinal haemorrhages occurred more often in the laser-alone group (42.9% vs. 9.4%, =0.002). Normal development of temporal retinal vessels was also observed in twelve eyes in the combined treatment group. No differences in late complications or refractive errors were observed between the groups.
Temporal Zone II-sparing laser treatment combined with IVB showed good early treatment outcome and temporal retinal vessels development.
背景/目的：本研究旨在探讨颞侧II区保留激光光凝联合玻璃体内注射贝伐单抗（IVB）治疗I区1型早产儿视网膜病变（ROP）的疗效。
分析37例婴儿74只眼的病历。仅纳入I区1型ROP婴儿。32只眼接受颞侧保留激光+IVB治疗。I区和颞侧II区均保留以尽量减少潜在视野缺损。42只眼按常规仅接受激光治疗。分析早期治疗效果、晚期并发症和屈光不正情况。
纳入患者的平均胎龄和出生体重分别为25.7±2.5周和798.8±440.2g。联合治疗组加号征消退更快（12.1±6.2天对25.6±21.3天，P=0.011），再次治疗需求更少（0%对23.8%，P=0.004）。仅激光治疗组视网膜/视网膜前出血更常见（42.9%对9.4%，P=0.002）。联合治疗组12只眼中颞侧视网膜血管也观察到正常发育。两组晚期并发症或屈光不正无差异。
颞侧II区保留激光治疗联合IVB显示出良好的早期治疗效果和颞侧视网膜血管发育。
